Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975639 | 0.86 | HPGD (0.46) | HPGDMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31429071 | 0.86 | HPGD (0.46) | HPGDMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31428784 | 0.85 | MAPT (0.52) | HPGDMAPTMEN1KMT2AERN1 | |
| SCHEMBL31428987 | 0.85 | RIPK1 (0.44) | HPGDERN1SMN1; SMN2GRM2ALDH1A1 | |
| SCHEMBL31428712 | 0.84 | GRM2 (0.49) | HPGDERN1SMN1; SMN2GRM2AR | |
| SCHEMBL31428742 | 0.84 | HPGD (0.47) | HPGDMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31428954 | 0.83 | CCNC (0.44) | HPGDKMT2AERN1SMN1; SMN2GRM2 | |
| SCHEMBL31429121 | 0.83 | AR (0.56) | HPGDMAPTMEN1KMT2AERN1 | |
| SCHEMBL31428994 | 0.83 | ERN1 (0.41) | HPGDMAPTMEN1KMT2AERN1 | |
| SCHEMBL31428711 | 0.82 | GRM2 (0.51) | HPGDERN1GRM2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HPGD 4233/4885MAPT 4513/4885MEN1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.